Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Genentech, Inc. Patents
Assignee:
Genentech, Inc.
Address:
South San Francisco, CA
No. of patents:
1972
Patents:












Patent Number Title Of Patent Date Issued
8092797 Anti-VEGF antibodies January 10, 2012
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological
8088618 Anti-IL 13 antibodies and uses thereof January 3, 2012
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also r
8088386 Treatment of complement-associated disorders January 3, 2012
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
8084200 Compositions and methods for the diagnosis and treatment of tumor December 27, 2011
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
8076066 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody ca December 13, 2011
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, pr
8075892 Treatment with anti-ErbB2 antibodies December 13, 2011
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and
8075890 Method for making humanized antibodies December 13, 2011
Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
8075888 Methods of treatment using antibodies to IL-17 homologous polypeptides December 13, 2011
The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising th
8071097 Apoptotic anti-IgE antibodies December 6, 2011
The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
8067664 PRO224 gene disruptions, and methods related thereto November 29, 2011
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A3
8067229 UCP4 November 29, 2011
The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins ("UCPs") and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypepti
8067199 Anti-IL13 antibodies and uses thereof November 29, 2011
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also r
8067002 Humanized anti-factor D antibodies November 29, 2011
The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders assoc
8063218 Imidazopyridine inhibitors of IAP November 22, 2011
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X.sub.1, X.sub.2, Y, Z R.sub.1, R.sub.2, R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.6, R.sub.6' and n ar
8063186 Antibodies to PRO7436 polypeptides November 22, 2011
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent
8048420 Monoclonal antibody November 1, 2011
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated
8044017 Protein purification October 25, 2011
A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
8034342 Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E October 11, 2011
The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecu
8030454 Anti-hedgehog antibodies October 4, 2011
The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.
8030023 Nucleic acid encoding DR5 antibodies and uses thereof October 4, 2011
The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
8029783 DR5 antibodies and articles of manufacture containing same October 4, 2011
The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
8012754 Antibody compositions September 6, 2011
A process for purifying an antibody is provided. In this process, a mixture containing the antibody and a contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) at low salt concentration. The antibody is eluted from the column in the fraction which does not
8012482 Humanized anti-TGF-beta antibodies September 6, 2011
Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
8012473 C3b antibodies and methods for the prevention and treatment of complement-associated disorders September 6, 2011
The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.
8008447 Crystallization of antibody or fragment thereof August 30, 2011
The present disclosure concerns methods of crystallization and/or concentration of antibody or antibody fragments. The methods comprise contacting an antibody or antibody fragment with a solution comprising a salt of a divalent cation. Crystals and/or protein gels of antibody or anti
8008004 Compositions and methods for the diagnosis and treatment of tumors of glial origin August 30, 2011
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumors of glial origin in mammals and to methods of using those compositions of matter for the same.
8007799 Vascular endothelial cell growth factor antagonists and uses thereof August 30, 2011
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF a
8007798 Treatment of complement-associated disorders August 30, 2011
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovas
8007795 Anti-tissue factor antibodies and methods of use thereof August 30, 2011
The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone
8007791 Prevention and treatment of complement-associated eye conditions August 30, 2011
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
7998931 Vascular endothelial cell growth factor antagonists and uses thereof August 16, 2011
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF a
7994286 Neuropilin antagonists August 9, 2011
Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
7994285 Anti-Notch3 antibodies August 9, 2011
The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines
7993834 Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 a August 9, 2011
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonis
7989595 Compositions and methods for the diagnosis and treatment of tumor August 2, 2011
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
7985840 Synthetic antibody phage libraries July 26, 2011
The invention provides comprising variant amino acids in CDRs of antibody variable domains. These polypeptides provide a source of great sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as
7982015 Compositions and methods for treatment of cancer July 19, 2011
The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal
7981418 Predicting response to a HER inhibitor July 19, 2011
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, wit
7977064 Disheveled PDZ modulators July 12, 2011
The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators.
7976838 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-.alpha. inhibito July 12, 2011
The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF.alpha.-inhibitor.
7973138 Antibodies July 5, 2011
The present invention relates to the use of VEGF antagonists and a novel anti-.alpha.5.beta.1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositio
7968094 Use of anti-tissue factor antibodies for treating thromboses June 28, 2011
Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment th
7960118 EGFR mutations June 14, 2011
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatmen
7956237 Gene disruptions, compositions and methods relating thereto June 7, 2011
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, P
7951917 Method for making multispecific antibodies having heteromultimeric and common components May 31, 2011
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a mul
7951916 Il-1 related polypeptides May 31, 2011
The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecul
7947866 Gene disruptions, compositions and methods relating thereto May 24, 2011
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, P
7947839 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods May 24, 2011
Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for
7947813 Polyelectrolyte precipitation and purification of proteins May 24, 2011
Methods are presented for isolating and purifying proteins by adding a polyelectrolyte to a cell culture fluid, such as a harvested cell culture fluid, and precipitating a protein-polyelectrolyte complex or a complex of impurities and the polyelectrolyte.
7947650 Article of manufacture May 24, 2011
The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs

 
 
  Recently Added Patents
Wireless communication system and wireless communication method
Cooling system for a room containing electronic data processing equipment
Stator core module, stator core assembly and process for assembling a stator core assembly
Drive device for vehicle
Non-contacting seals for geared gas turbine engine bearing compartments
Determining page faulting behavior of a memory operation
Method to increase pathogen resistance in plants
  Randomly Featured Patents
Linear time counter indicating tape running amount
Method for forwarding broadcast packets in a bridged IP network
Placing a computer system into a sleeping state
Operating method for non-volatile memory unit
Method, system and processor for processing network address translation service
Quinolone carboxylic acid derivatives
Protective hood with adjustable visor
Diamond-like carbon (DLC) hardmask and methods of fabrication using same
Method and apparatus for performing N bit by 2*N-1 bit signed multiplication
Roofing membrane puller and method of use